{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-003344","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.268682+00:00","generated_at":"2026-05-24T10:14:46.092811+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MetaVia reports FY2024 net loss $27.6M; cash $16.0M funds into Q3 2025; DA-1726 data expected April","bullets":["Net loss $27.6M ($3.56/share) vs $12.5M ($2.46/share) in 2023; R&D expenses rose to $21.6M from $9.2M.","Cash $16.0M as of Dec 31, 2024 (down from $22.4M); expected to fund operations into Q3 2025.","DA-1726: Top-line data from additional MAD Part 2 cohorts expected April 2025; proof-of-concept study planned Q4 2025.","DA-1241: Phase 2a in MASH met primary endpoint (ALT reduction); full data at medical meeting 2025; FDA end-of-Phase 2 meeting H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-003344","json":"https://secwatch.observer/filing/0001558370-25-003344.json","markdown":"https://secwatch.observer/filing/0001558370-25-003344.md","text":"https://secwatch.observer/filing/0001558370-25-003344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837025003344/0001558370-25-003344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837025003344/mtva-20250320x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:14:46.092811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}